Talazoparib (oral, 1 mg once daily [QD]) is approved as a monotherapy for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with a germline BRCA1/2 mutation in the US, EU, and other countries [9, 10]. This evidence concerns the gene ERBB2 and breast cancer.